We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
QIAGEN Banks on Tie-Ups & Product Launches, Competition Rife
Read MoreHide Full Article
On Oct 10, we issued an updated research report on Netherlands-based molecular diagnostics provider QIAGEN (QGEN - Free Report) . The company offers innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions.
We are upbeat about QIAGEN’s partnership and co-marketing agreement with CENTOGENE AG to boost its bioinformatics portfolio. Also, we are encouraged to note that post the receipt of FDA approval in June, QIAGEN announced the complete launch of the fourth generation of its blood test for tuberculosis (TB) infection — QuantiFERON-TB Gold Plus (QFT-Plus) — in the United States.
Moreover, the company’s strategic focus to drive growth through Sample to Insight offerings buoys optimism. QIAGEN is forming collaborations in the personalized homecare space as well.
QIAGEN currently markets products in more than 100 countries. In the last reported second quarter of 2017, the company witnessed growth across all international regions, including the top seven emerging markets.
On the flip side, over the last three months, QIAGEN has been trading below the broader industry. As per the latest share price, the company has gained 2.9%, compared to 7.1% gain of the broader industry. Moreover, adverse currency translation continues to be a drag on overall sales. Furthermore, declining HPV sales in the United States continues to be a drag. Competitive landscape and heavy dependence on collaborations continue to be concerns.
Abbott has a long-term expected earnings growth rate of 10.7%. The stock has rallied roughly 35.2% over the last year.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock has gained 40.8% last year.
Thermo Fisher has a long-term expected earnings growth rate of 11.7%. The stock has gained 25.3% last year.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
QIAGEN Banks on Tie-Ups & Product Launches, Competition Rife
On Oct 10, we issued an updated research report on Netherlands-based molecular diagnostics provider QIAGEN (QGEN - Free Report) . The company offers innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions.
We are upbeat about QIAGEN’s partnership and co-marketing agreement with CENTOGENE AG to boost its bioinformatics portfolio. Also, we are encouraged to note that post the receipt of FDA approval in June, QIAGEN announced the complete launch of the fourth generation of its blood test for tuberculosis (TB) infection — QuantiFERON-TB Gold Plus (QFT-Plus) — in the United States.
Moreover, the company’s strategic focus to drive growth through Sample to Insight offerings buoys optimism. QIAGEN is forming collaborations in the personalized homecare space as well.
QIAGEN currently markets products in more than 100 countries. In the last reported second quarter of 2017, the company witnessed growth across all international regions, including the top seven emerging markets.
On the flip side, over the last three months, QIAGEN has been trading below the broader industry. As per the latest share price, the company has gained 2.9%, compared to 7.1% gain of the broader industry. Moreover, adverse currency translation continues to be a drag on overall sales. Furthermore, declining HPV sales in the United States continues to be a drag. Competitive landscape and heavy dependence on collaborations continue to be concerns.
Zacks Rank & Other Key Picks
QIAGEN currently carries a Zacks Rank #2 (Buy). Other top-ranked stocks in the medical sector are Abbott (ABT - Free Report) , IDEXX Laboratories, Inc. (IDXX - Free Report) and Thermo Fisher Scientific Inc. (TMO - Free Report) . Abbott, IDEXX Laboratories and Thermo Fisher carry a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Abbott has a long-term expected earnings growth rate of 10.7%. The stock has rallied roughly 35.2% over the last year.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock has gained 40.8% last year.
Thermo Fisher has a long-term expected earnings growth rate of 11.7%. The stock has gained 25.3% last year.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>